Abstract:AbstractAlzheimer’s disease (AD) is a progressive neurodegenerative disease that represents the most common form of dementia among the elderly. Despite the fact that AD was studied for decades, the underlying mechanisms that trigger this neuropathology remain unresolved. Since the onset of cognitive deficits occurs generally within the 6th decade of life, except in rare familial case, advancing age is the greatest known risk factor for AD. To unravel the pathogenesis of the disease, numerous studies use cellular and animal models based on genetic mutations found in rare early onset familial AD (FAD) cases that represent less than 1 % of AD patients. However, the underlying process that leads to FAD appears to be distinct from that which results in late-onset AD. As a genetic disorder, FAD clearly is a consequence of malfunctioning/mutated genes, while late-onset AD is more likely due to a gradual accumulation of age-related malfunction. Normal aging and AD are both marked by defects in brain metabolism and increased oxidative stress, albeit to varying degrees. Mitochondria are involved in these two phenomena by controlling cellular bioenergetics and redox homeostasis. In the present review, we compare the common features observed in both brain aging and AD, placing mitochondrial in the center of pathological events that separate normal and pathological aging. We emphasize a bioenergetic model for AD including the inverse Warburg hypothesis which postulates that AD is a consequence of mitochondrial deregulation leading to metabolic reprogramming as an initial attempt to maintain neuronal integrity. After the failure of this compensatory mechanism, bioenergetic deficits may lead to neuronal death and dementia. Thus, mitochondrial dysfunction may represent the missing link between aging and sporadic AD, and represent attractive targets against neurodegeneration.

Editorial: Mitochondrial and Lysosomal Dysfunction in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Strategies

Mitochondrial dysfunction as a therapeutic strategy for neurodegenerative diseases: Current Insights and Future Directions

Molecular mechanisms of mitophagy and its roles in neurodegenerative diseases

Editorial: Molecular and Cellular Interactions of Myelin in Neurodevelopmental & Neurodegenerative Disorders

Mitochondrial dysfunction in Alzheimer's disease: Role in pathogenesis and novel therapeutic opportunities

Molecular mechanisms of mitochondrial homeostasis regulation in neurons and possible therapeutic approaches for Alzheimer's disease

Mitochondrial Dysfunction: Common Final Pathway in Brain Aging and Alzheimer’s Disease—Therapeutic Aspects

Role of mitophagy in mitochondrial quality control: Mechanisms and potential implications for neurodegenerative diseases

Modulation of Mitochondrial Function as a Therapeutic Strategy for Neurodegenerative Diseases

Mitochondrial Dynamics: A Key Role in Neurodegeneration and a Potential Target for Neurodegenerative Disease

Exploring Mitochondrial Quality in Aging and Neurodegenerative Diseases

Oxidative Stress in Neurodegenerative Diseases: From a Mitochondrial Point of View

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Insights into the Pathogenesis of Neurodegenerative Diseases: Focus on Mitochondrial Dysfunction and Oxidative Stress

Mitochondrial Dynamics in Brain Cells During Normal and Pathological Aging

Mitochondrial dysfunction: mechanisms and advances in therapy

Mitophagy Regulates Neurodegenerative Diseases

Abnormalities of Mitochondrial Dynamics in Neurodegenerative Diseases

Signaling Pathways Concerning Mitochondrial Dysfunction: Implications in Neurodegeneration and Possible Molecular Targets

Mitophagy: An Emerging Role in Aging and Age-Associated Diseases

Mitochondrial dysfunction: the missing link between aging and sporadic Alzheimer’s disease